Results 101 to 110 of about 7,679 (193)
Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical ...
Llanos JP +6 more
doaj
Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators
Allergy, EarlyView.
Jaime Bernaola +14 more
wiley +1 more source
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma [PDF]
Airidas Rimkunas,1 Andrius Januskevicius,1 Egle Vasyle,1 Jolita Palacionyte,2 Virginija Kalinauskaite-Zukauske,2 Skaidrius Miliauskas,2 Kestutis Malakauskas1,2 1Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health ...
Palacionyte J +6 more
core +1 more source
The spectrum of therapeutic activity of mepolizumab [PDF]
Introduction: The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils production, activation, and survival, which is associated with
Cavaliere C. +7 more
core +1 more source
Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE
Background: In the phase III SYNAPSE study, mepolizumab plus standard of care reduced total endoscopic nasal polyp score (NPS) versus that with placebo in patients with chronic rhinosinusitis with nasal polyps.
Amber U. Luong, MD, PhD +8 more
doaj +1 more source
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia [PDF]
BACKGROUND Eosinophilic inflammation, which may be a consequence of interleukin-5 action, is a characteristic feature of some forms of asthma. However, in three previous clinical trials involving patients with asthma, blockade of this cytokine did not ...
O'Byrne, Paul M. +7 more
core +1 more source
Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report [PDF]
Shota Kaburaki, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Kazuo Kasahara, Masahiro Seike Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanCorrespondence: Shota Kaburaki, Department of ...
Kamio K +5 more
core +1 more source
Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis
Clinical &Experimental Allergy, EarlyView.
J. I. Olydam +3 more
wiley +1 more source

